133
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Sulforaphane derivatives containing triazaphosphaadamantane (PTA) or o-carborane substituent

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 554-556 | Received 21 Oct 2021, Accepted 23 Oct 2021, Published online: 26 Dec 2021

References

  • (a) Kiełbasiński; P.; Łuczak; J.; Cierpiał T.; Błaszczyk J.; Sieroń, L.; Wiktorska, K.; Lubelska, K.; Milczarek, M.; Chilmonczyk, Z.; New Enantiomeric Fluorine-Containing Derivatives of Sulforaphane: Synthesis, Absolute Configurations and Biological Activity. Eur. J. Med. Chem. 2014, 76, 332–342; (b) Łuczak, J.; Kiełbasiński, P.; Cierpiał, T.; Pochodne Sulforafanu, Ich Prekursory Oraz Sposób Ich Wytwarzania. Polish Patent PL401114 (A1) 2015.
  • (a) Cierpiał, T.; Łuczak, J.; Kwiatkowska, M.; Kiełbasiński, P.; Śliwka, L.; Wiktorska, K.; Chilmonczyk, Z.; Milczarek, M.; Karwowska, K.; Organofluorine Isoselenocyanate Analogues of Sulforaphane: Synthesis and Anticancer Activity. ChemMedChem 2016, 11, 2398–2409; (b) Cierpiał, T.; Kiełbasiński, P.; Łuczak, J.; Wiktorska, K.; Śliwka, L.; Chilmonczyk, Z.; Milczarek, M.; Karwowska, K.; Nowe analogi Sulforafanu, Ich Prekursory, Sposób Ich Wytwarzania Oraz Postać Farmaceutyczna. Polish Patent PL235779 (B1) 2020.
  • Cierpiał, T.; Kiełbasiński, P.; Wiktorska, K.; Lubelska, K.; Chilmonczyk, Z. Nowe Analogi Sulforafanu, Sposób Ich Wytwarzania, Ich Zastosowanie Oraz Postać Farmaceutyczna. Polish Patent PL235212, 2020.
  • Ang, W.; Dyson, P. Classical and Non-Classical Ruthenium-Based Anticancer Drugs: Towards Targeted Chemotherapy. Eur. J. Inorg. Chem. 2006, 2006, 4003–4018. DOI: 10.1002/ejic.200600723.
  • (a) Sivaev, I. B.; Bregadze, V. V. ; Polyhedral Boranes for Medical Applications: Current Status and Perspectives. Eur. J. Inorg. Chem. 2009, 11, 1433–1450; (b) Leśńikowski, Z. J.; Challenges and Opportunities for the Application of Boron Clusters in Drug Design. J. Med. Chem. 2016, 59, 7738−7758; (c) Leśńikowski, Z. J.; Recent developments with boron as a platform for novel drug design. Exp Opin Drug Discov. 2016, 11, 569–578.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.